Halozyme Therapeutics (HALO) investor relations material

Financial performance and growth outlook

• Forecasting $1.7–$1.8 billion in 2024 revenue, representing 22%–30% year-over-year growth, driven by royalties from partnered products and ENHANZE, with adjusted EBITDA expected at $1.1–$1.2 billion.

• Three main products—DARZALEX FASPRO, VYVGART Hytrulo, and Perjeta—are currently the primary growth drivers, with Perjeta's U.S. conversion reaching 52% and targeted for 60% by 2028.

• Four recently launched products, including Opdivo, OCREVUS, RYBREVANT, and Tecentriq subcutaneous, are expected to contribute significantly to growth starting in 2026.

• New ENHANZE deals signed at the end of 2025 and anticipated additional deals in 2026 will support long-term growth, with new product launches expected through 2029–2030 and beyond.

• Royalties from current and future products are projected to provide robust profitability and recurring revenue streams into the 2040s.

Product innovation and market expansion

• Subcutaneous (SubQ) delivery is transforming patient experience, reducing treatment times from hours to minutes and enabling at-home administration, especially for VYVGART and OCREVUS.

• VYVGART's pre-filled syringe has driven rapid adoption and market expansion, with analysts projecting growth from $4 billion to $8 billion in approved indications.

• OCREVUS SubQ is expanding the market by attracting new patients and physicians, with Roche expecting a $2 billion increase in sales due to SubQ adoption.

• RYBREVANT SubQ has improved safety and reduced infusion-related reactions, supporting J&J's ambition to grow the brand from under $1 billion to $5 billion.

• Pharma and biotech interest in SubQ delivery is increasing, with ENHANZE and new technologies like Hypercon and Surf Bio attracting new partners and expanding the addressable market.

Pipeline development and partnerships

• Seven ENHANZE products are in development, including candidates from argenx, Takeda, and ViiV, with launches expected from 2027–2028 and six new ENHANZE phase 1 starts projected for 2026.

• By 2028, the portfolio is expected to include 40 approved or in-development drugs, reflecting strong momentum and partner engagement.

• At least three new ENHANZE deals and one to two Hypercon deals are anticipated in 2026, following three deals closed at the end of 2025 with Takeda, Skye Bioscience, and Merus.

• Current partners are expanding their use of ENHANZE, and new partners are joining as the industry embraces SubQ delivery.